Due to the increasingly adverse environment, BIOCRYST PHARMA is downgraded to Neutral despite adding a new star
BIOCRYST PHARMA (US), a company active in the Biotechnology industry, adds a star(s) at the fundamental level albeit its general evaluation is downgraded given the increasingly adverse environment. The independent financial analyst theScreener has awarded a new star(s) to the company, which now shows 4 out of 4 possible stars; its market behaviour remains unchanged and can be considered as moderately risky. theScreener believes that adding a star(s) does not offset the increasingly adverse environment and downgrades the title's overall rating to Neutral. As of the analysis date January 11, 2022, the closing price was USD 16.43 and its expected value was estimated at USD 13.23.BioCryst Pharmaceuticals is a biotechnology company that discovers oral, small-molecule medicines. The company focuses on oral treatments for rare diseases in which unmet medical needs exist and an enzyme plays the main role in the biological pathway of the disease. The company's drug/drug candidates include: Berotralstat (BCX7353), an oral serine protease inhibitor targeting kallikrein that is being developed as a once-daily oral therapy for the prevention of Hereditary Angioedema; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; and BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.